Author

U. Rand

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Microbiology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

L. Cicin-Sain· 5 shared Y. Kim· 3 shared D. Meier· 2 shared E. V. Wenzel· 2 shared F. Bertoglio· 2 shared G. Roth· 2 shared G. Russo· 2 shared K. D. R. Roth· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBioengineering

L. Cicin-Sain

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses

B. Jiang, M. J. Schmitt, U. Rand, C. Company, M. Grossmann, M. Serresi, L. Cicin-Sain, G. Gargiulo

The paper identifies pharmacological modulators of epithelial immunity by analyzing SARS-CoV-2 infection responses using synthetic genetic reporters and drug screens.

bioRxiv · Nov 5, 2022Bioengineering

Fibroblastic cells are a site of mouse cytomegalovirus in vivo lytic replication and latent persistence oppositely regulated by Stat1

K. M. Sitnik, F. Krstanovic, N. Goedecke, U. Rand, T. Kubsch, H. Maas, Y. Kim, I. Brizic, L. Cicin-Sain

This study shows that fibroblastic cells support both lytic and latent mouse cytomegalovirus (MCMV) infection, with Stat1 regulating the switch between these states.

bioRxiv · Jun 29, 2022 · PreprintMicrobiology

Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity

U. Rand, S. Y. Kupke, H. Shkarlet, M. D. Hein, T. Hirsch, P. Marichal-Gallardo, L. Cicin-Sain, U. Reichl, D. Bruder

This study shows that influenza A virus defective interfering particles inhibit SARS-CoV-2 replication in vitro by enhancing innate immunity through JAK/STAT signaling.

bioRxiv · Feb 19, 2021Microbiology

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

F. Bertoglio, V. Fühner, M. Ruschig, P. A. Heine, L. Abasi, T. Klünemann, U. Rand, D. Meier, N. Langreder, S. Steinke, R. Ballmann, K.-T. Schneider, K. D. R. Roth, P. Kuhn, P. Riese, , M. Hust

The paper describes the selection of a SARS-CoV-2 neutralizing antibody from COVID-19 patients using phage display, showing it binds the ACE2-RBD interface and remains effective against emerging RBD mutations.

bioRxiv · Dec 3, 2020Bioengineering

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

F. Bertoglio, D. Meier, N. Langreder, S. Steinke, U. Rand, L. Simonelli, P. A. Heine, R. Ballmann, K.-T. Schneider, K. D. R. Roth, M. Ruschig, P. Riese, K. Eschke, Y. Kim, D. Schaeckermann, , M. Hust

The paper identifies potent SARS-CoV-2 neutralizing antibodies from pre-pandemic human donors that bind the RBD-ACE2 interface, showing high neutralization efficacy in vitro.

bioRxiv · Jun 5, 2020Biochemistry